Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFIC: Durvalumab in Stage III NSCLC
NCT02125461Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2014
- Primary completion
- Feb 2017
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Durvalumab with Placebo (2 arms). Primary endpoints: Progression Free Survival up to 3 years and Overall Survival up to 4 years. Started May 2014; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02125461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02125461.